Financial Performance - For the six months ended September 30, 2025, the group's revenue was approximately HKD 284.6 million, a significant increase of 68.5% compared to HKD 169.5 million for the same period in 2024[8]. - The net profit for the same period was approximately HKD 20.8 million, representing a 26.5% increase from HKD 16.4 million in the previous year[8]. - The group reported a basic earnings per share of HKD 2.61, up from HKD 2.05 in the previous year, reflecting improved profitability[9]. - For the six months ended September 30, 2025, the company reported a profit of 20,840,000 HKD, compared to 16,430,000 HKD for the same period in 2024, representing a year-over-year increase of 27.5%[12]. - Revenue from treatment services reached 280,404,000 HKD, a significant increase of 71.7% compared to 163,302,000 HKD in the previous year[18]. - Net profit for the same period was approximately HKD 20.8 million, up from HKD 16.4 million in the previous year, primarily due to increased revenue[49]. Dividends and Shareholder Information - The board of directors did not recommend the distribution of dividends for the six months ended September 30, 2025, consistent with the previous year[8]. - The company did not declare any dividends for the six months ended September 30, 2025, consistent with the previous year[23]. - The major shareholders, Mr. Ye and Ms. Fu, each hold 63.28% of the company's shares through a controlled corporation, totaling 506,200,000 shares[71]. - Equal Joy holds 506,200,000 shares, representing 63.28% of the company's equity[74]. Assets and Liabilities - Total assets as of September 30, 2025, amounted to HKD 330.3 million, up from HKD 329.8 million as of March 31, 2025[10]. - Current liabilities decreased to HKD 186.4 million from HKD 176.9 million as of March 31, 2025, indicating improved liquidity management[11]. - The group's total equity increased to HKD 126.9 million from HKD 106.1 million, indicating a stronger financial position[11]. - The total outstanding debt as of September 30, 2025, was approximately HKD 131.6 million, including lease liabilities of HKD 80.4 million and bank borrowings of HKD 51.2 million[50]. - The debt-to-equity ratio was 103.7% as of September 30, 2025, up from 87.1% as of March 31, 2025[60]. Operational Highlights - The group’s inventory increased to HKD 22.5 million from HKD 10.8 million, reflecting a strategic buildup of stock to meet anticipated demand[10]. - Trade receivables rose to HKD 87.8 million from HKD 80.9 million, suggesting an increase in sales and customer base[10]. - The company opened several new centers to expand its operations, including two new premium centers in Tsim Sha Tsui and Central in April 2023, and plans to open additional centers in various locations by March 31, 2025[38]. - The company launched a new brand "perFACE ESSENTIAL" in 2025, which combines innovative medical technology and expertise to offer a variety of treatment solutions[38]. Employee and Operational Costs - The company incurred total employee costs of 115,856,000 HKD, which is an increase of 90% from 61,059,000 HKD in the previous year[21]. - Employee costs for the six months ended September 30, 2025, were approximately HKD 115.9 million, an increase from HKD 61.1 million in the previous year, mainly due to a rise in the number of employees[44]. - Other expenses for the same period totaled approximately HKD 69.2 million, up from HKD 41.3 million, driven by increased marketing activities and consultation fees paid to doctors[48]. Cash Flow and Financing - The company recorded a net cash outflow from operating activities of 17,571,000 HKD for the six months ended September 30, 2025, compared to a net inflow of 45,283,000 HKD in the same period of 2024[13]. - Total cash and cash equivalents at September 30, 2025, were 40,516,000 HKD, a decrease from 40,615,000 HKD at the beginning of the period[13]. - The company incurred financing costs of HKD 2.0 million, an increase from HKD 1.2 million, which may indicate higher borrowing levels[9]. Governance and Compliance - The group maintained compliance with corporate governance codes and has established an audit committee to oversee financial reporting[67][69]. - The board of directors includes executive and independent non-executive members, ensuring diverse governance[87]. - No directors or their associates are engaged in any business that directly or indirectly competes with the group's business, maintaining compliance with GEM listing rules[87]. Stock Options and Share Plans - The stock option plan allows for a maximum of 80,000,000 shares to be granted, which is 10% of the issued shares as of the report date[76]. - No stock options have been granted, exercised, or canceled since the adoption of the stock option plan[83]. - The stock option plan is valid for ten years from the date of adoption unless terminated by shareholder resolution[76]. - The exercise price of each stock option must be at least the higher of the closing price on the grant date or the average closing price over the five trading days prior to the offer date[82]. - The company has no outstanding stock options, warrants, or convertible securities as of September 30, 2025[83].
亮晴控股(08603) - 2026 - 中期财报